We now have assembled a cohort of 50  further affected individuals with variants in SCAF4 (Fig. 1A) and thus considerably broaden the molecular and clinical spectrum of the SCAF4-associated NDD. This evidence concerns the gene SCAF4 and Neurodevelopmental delay.